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This is a commentary discussing the article published in Thrombosis Journal by Subramanian et al. [Thrombosis
Journal 2012, 10:15].The need for post-operative thromboembolic prophy-
laxis in orthopaedic surgery is beyond debate. Post-
operative thrombosis is prevalent in these patients. In
the absence of thromboprophylaxis, the incidence of
venographically confirmed deep vein thrombosis
(DVT) in the first 7 to 14 days following surgery is
about 40-60%. About half of these thrombi become
symptomatic. In most cases DVT is diagnosed within a
period of two months after the patients’ discharge from
hospital [1].
Guidelines on prophylaxis of venous thrombo-
embolism that have been published by at least four
different organisations established in the field of med-
ical research, all agree on the need for post-operative
prophylaxis [2-5].
Current prophylactic treatment is highly effective, and
a significant reduction in the venous thromboembolism
(VTE) incidence can therefore be reached by the use of
adequate prophylaxis [6,7].
However, despite the various guideline recommenda-
tions and readily available efficacious medication, the
use of preventive measures against VTE in clinical prac-
tice has been found to be sub-optimal in several
instances. A retrospective study by Yu et al. [8] found
that the overall compliance with (ACCP) guidelines for
the prevention of VTE in six American hospitals was
only 13.3%, ranging from 2.8% for neurosurgery to
52.4% for orthopaedic surgery. A survey amongst sur-
geons in the United Kingdom by Sharif et al. [9] showed* Correspondence: arina.tencate@maastrichtuniversity.nl
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distribution, and reproduction in any mediumthat only 7% of respondents were adhering to NICE
guidance after hip fracture surgery and 44% after hip
arthroplasty.
Therefore, the stated rationale and considerations by
the authors of the article published Thrombosis Journal
on the 12 month review of a modified protocol using
low dose Dabigatran etexilate in postoperative thrombo-
embolic prophylaxis in joint replacement surgery, to de-
viate from the NICE guideline, seem legitimate [10]. On
the one hand, the deviation from the guidelines is in
favour of increased compliance with protocol by in-
hospital (junior) staff. On the other hand, enhanced pa-
tient compliance and adherence in the out of hospital
setting is anticipated by avoiding the need for self admi-
nistered injections at home.
Usually guidelines fall behind with innovations in clin-
ical practice. After the introduction of new treatment
modalities some time passes before synthesized evidence
finds its way into guideline recommendations. In the
case of the novel oral anticoagulant drugs such as dabi-
gatran and rivaroxaban this implementation into guide-
lines has been relatively swift.
At this moment there is lack of day-to-day clinical
experience with the newly introduced drugs and there-
fore clinical evidence is less unequivocal. Clinical prac-
tice usually differs from the setting of a clinical trial.
Post surgical gastrointestinal upset and vomiting may
reduce the effectiveness of oral antithrombotic therapy.
To start prophylactic treatment post surgery with sub-
cutaneous administered LMWH is therefore an attract-
ive alternative.BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ment of two individually established safe and efficient
therapeutic treatment modalities is understandable, but
has a number of methodological shortcomings. Patient
management was instituted without any preliminary
studies, such as to identify the optimal, safe and effec-
tive, dosing strategy for the overlap of two different
treatment modalities. In addition, a pragmatic, non-
evidence based, choice was made for the single use of a
low dose of 150 mg dabigatran once daily, irrespective of
patient characteristics such as bodyweight, age or kidney
function. On the other hand, all consecutive patients
who met the inclusion criteria were managed according
to the protocol, minimising selection bias. Data on com-
plications such as VTE, bleeding, transfusion rates, peri-
procedural infections and mortality were prospectively
collected and reviewed by an independent reviewer to
control for bias.
In parallel to the article by Subramanian et al., com-
parable clinical experience was gained in the United
States, in this case in the setting of a clinical study, with
similar alternative treatment strategies, bridging the
periprocedural period with LMWH and making the
transition to oral anticoagulant treatment before hospital
discharge [11]. This study investigated the optimal inter-
val for a safe overlap in anticoagulant activity between
the LMWH and the oral anticoagulant drug rivaroxaban.
The underlying rationale for the study being essentially
the same: adapting the strategy to the requirements of
day-to-day clinical practice.
The need for (observational) data on the novel oral
anticoagulant drugs derived from clinical practice is
widely recognized. Despite methodological shortcom-
ings, the recent Subramanian et al. article adds to our
knowledge on the everyday use of the novel oral anti-
coagulant medication and shows that the choice of
prophylactic treatment does depend on clinical circum-
stances but also on patient preference.
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